Safety and Immunogenicity of Live Attenuated Influenza H5N2

Mahidol University

Status and phase: Completed; Phase 2

Conditions: Influenza Due to Influenza A Virus Subtype H5N2

Treatments: Biological: Avian Flu Vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT01841918

GPO AVIAN FLU Vaccine-V02-2

Details and patient eligibility

About

The purpose of this study is to evaluate immune response and safety of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, Thailand in healthy Thais.

Full description

It is a double blind randomized study using 7.5-8.5 log EID50 dose which is the same dose as being tested in phase I.

150 participants (100 vaccinees and 50 placebos) age 18-49 years old will be enrolled. All will be separated in 4 batches; Batch 1: 36 participants (24 vaccinees and 12 placebos) Batch 2: 38 participants (25 vaccinees and 13 placebos) Batch 3: 38 participants (25 vaccinees and 13 placebos) Batch 4: 38 participants (26 vaccinees and 12 placebos)

Each batch will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart. Total follow up is 60 day.

Enrollment: 150 patients

Sex: All

Ages: 18 to 49 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy
• Age 18-49 years old
• Having Thai ID card or equivalent
• Are seronegative to the specific H5 influenza virus determined by antibody titer less than 1:40 by HAI test to the corresponding antigen.
• Anti HIV - Negative
• All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not more than 1.5 times of normal value)
• Able to read and write and sign written informed consent.

Exclusion criteria

• Known history of egg allergy
• Having had recently influenza infection confirmed as H5
• History of bronchial asthma
• History of chronic lung diseases
• History of chronic rhinitis
• History of immunodeficiency state
• History of immunosuppression
• History of heavy smoking (more than 5 rolls per day)
• History of alcoholic (pure drink 200 ml per day)
• Acute infectious and noninfectious diseases (within 2 weeks)
• Exacerbation of chronic diseases or cancer or HIV positives
• Anamnestic leukocytosis, hepatitis B and C positives
• The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment
• Participation in other research study or stop participant less than 1 month
• Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding
• Any concomitant medication with Aspirin
• Poultry workers

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

150 participants in 2 patient groups, including a placebo group

A/17/turkey/Turkey/05/133 (H5N2)

Experimental group

Description:

100 participants will be admitted in the isolation ward for 5 days after each immunization mainly for safety assessment. Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) will be given by intranasal route 28 days apart and will be followed for the total of 60 days.

Treatment:

Biological: Avian Flu Vaccine

Placebo

Placebo Comparator group

Description:

50 participants will be admitted in the isolation ward for 5 days after each administered placebo mainly for safety assessment. Two doses placebo will be given by intranasal route 28 days apart and will be followed for the total of 60 days.

Treatment:

Biological: Avian Flu Vaccine